Abstract Young injection drug users (IDUs) are at risk for acquiring blood-borne diseases like HIV and Hepatitis C. Little is known about the population prevalence of young IDUs. We (1) 
Introduction
Research indicates that young injection drug users (IDUs) differ in their risk behavior from their older counterparts, and have a very high risk for HIV, HCV, STIs and drug overdose [1] [2] [3] [4] [5] [6] [7] [8] . They are less aware of the dangers of injecting drugs and how to reduce their risk, and more likely to share syringes and drug preparation equipment. They inject frequently, have multiple sexual partners, and exchange sex for money or drugs [9] [10] [11] [12] .
Increases in the number of young IDUs are likely to increase the numbers of HIV/AIDS, cirrhosis, and hepatocellular carcinoma cases, the number of IDUs needing social and medical services, and the number of overdose deaths [13] . Therefore, it is very important to monitor the prevalence of IDU among youth.
Data on the prevalence of young IDUs in US geographic areas are rare. The National Survey on Drug Use and Health (NSDUH) provides annual estimates of numbers of young IDUs in the US, but these data are not suitable to measure change as: (a) data are derived from a household survey with well-known sampling and self-report limitations; and (b) NSDUH acknowledge the data are not suitable for longitudinal analyses, given changes in data collection methods over time. These limitations have been discussed in detail elsewhere [14] [15] [16] [17] [18] .
This study: (1) describes a method of estimating the population prevalence of young IDUs aged 15-29 in 95 large metropolitan statistical areas (MSAs) annually over an 11-year period (1992-2002) ; (2) validates the resulting population prevalence estimates; and (3) conducts exploratory analyses of a hypothesis that young IDU prevalence increased after HAART was discovered.
Providing public health and harm reduction advocates with young IDUs estimates can: (1) assist efforts to plan young IDU-related health services; (2) bring about a better understanding of young IDU drug-related health problems; and (3) assist research in exploring the social and structural determinants of young IDU-related prevalence [19, 20] .
Methods

Unit of Analysis
The MSA is the unit of analysis. The U.S. Office of Management and Budget defines an MSA as a set of adjacent counties that collectively form a single cohesive socioeconomic unit and include at least one central city home to 50,000 people or more [21, 22] . We chose MSAs as a unit of analysis because they are salient epidemiologic units for the study of injecting: injection-related epidemics like HIV vary widely across MSAs, and many suburban injectors travel to the central city to receive services and engage in drug-related activity [23, 24] .
This study includes 95 of the 96 U.S. MSAs whose population exceeded 500,000 in 1992. These are home to almost two thirds of the U.S. population. One MSA, San Juan, was excluded due to data unavailability.
Overview of the Data Series Used and Estimating Procedure
We used two data series to estimate the population prevalence of young IDUs. Both data-series report on service episodes rather than on unique individuals: We used a 3-step approach similar to that used in some of our previous studies to estimate the annual population prevalence of young IDUs in each MSA from 1992 to 2002 [14, 27, 28] .
Step 1: For both TEDS and CTS, separately, we calculated the annual proportions of IDUs receiving these services at drug treatment and HIV testing and counseling sites who were aged 15-29 years in each MSA.
Step 2: To calculate the number of young IDUs, we then multiplied these proportions of young IDUs by previously-calculated estimates of the total number of IDUs in each MSA and year [27] . To estimate the population prevalence of young IDUs for TEDS and CTS, we divided the number of young IDUs using each service by the size of their respective ''at risk'' populations (i.e., youth aged 15-29) for each MSA and year.
Step 3: For the final estimates, we used the predicted values from a linear mixed model (LMM) that included both TEDS and CTS based estimates.
Step 1 Estimating the proportions of young IDUs in TEDS and CTS.
First, for TEDS, we calculated the proportion of young IDUs aged 15-29 among all IDUs (regardless of age) entering treatment in 95 MSAs from 1992 to 2002. We then calculated the proportion of young IDUs among all IDUs receiving HIV counseling and testing from the CTS data.
To avoid small denominator problems, the TEDS and CTS databases were processed with a criterion that, if any MSAs in any year from 1992 to 2002 had less than 5 IDUs (regardless of age), we marked that cell as missing. After applying the criteria, there were approximately 5% missing cells in TEDS and 8% missing cells in CTS. 1 Step 2 Estimating the numbers and population prevalence of young IDUs from TEDS and CTS proportions.
To estimate the total number of young IDUs, previously published data on the total number of IDUs were used [28] . We briefly discuss how this earlier paper calculated the total numbers of IDUs in 96 MSAs for each year 1992-2002.
The study used a multiplier/allocation method to estimate the national population prevalence of IDUs from 1992 to 2002 from existing data on the number of injectors living in the U.S. in 1992 and in 1998, and from annual data on injectors' encounters with health services and with the criminal justice system [27] [28] [29] . Then, to estimate the prevalence of IDUs in 96 large MSAs from 1992 to 2002, we allocated these totals among the 96 MSAs (and the rest of the country) using four different types of data : (1) Centers for Disease Control HIV CTS data; (2) SAM-SHA's Uniform Facility Data Set (UFDS) and TEDS data; (3) CDC data on diagnoses of IDUs with HIV/AIDS; and (4) an estimate derived from published estimates of the number of injectors living in each MSA in 1992 [29] and in 1998 [28] . Each series was smoothed over time using loess regression and the mean value of the four component estimates was taken as the best estimate of the prevalence of IDUs for each MSA and year [27] .
Where data were not missing, we multiplied our estimated proportions of IDUs who were aged 15-29 in the TEDS data by these previous estimates of the total number of IDUs in each MSA annually from 1992 to 2002. Similarly, we then multiplied the proportion of IDUs who were young in the CTS data by the estimated total IDUs in the MSA to create a second estimate of the number of young IDUs.
We then calculated the population prevalence of young IDUs separately for each data series by dividing the estimated number of IDUs in the MSA by the population of young people aged 15-29 of that MSA in that year (and multiplying the result by 10,000), using data from the US Census Population Estimates Program [30] .
Step 3 Final estimate, using a restricted-maximum-likelihood average based on LMM.
To calculate the final estimates of young IDUs per 10,000 populations in each MSA in each year, we used LMM [31] [32] [33] [34] . The LMM combined the population prevalence of young IDUs calculated from TEDS and CTS to form a single combined estimate while adjusting for missing data. Once we combined the data series we had 1,045 cells ? 1,045 cells = 2,090 cells. To distinguish the two sources of data, we created a source indicator, coded 0.5 if representing TEDS and -0.5 if representing CTS. We describe our LMM briefly here:
where E (Y ijk |time, data series) is the mean population prevalence of young IDUs in i MSA, j year and k estimates from TEDS or CTS; b 0 the mean population prevalence of young IDUs in 1997; b 1 the population prevalence of young IDUs linear slope; b 2 the population prevalence of young IDUs quadratic slope; b 3 the difference in young IDU prevalence estimated from TEDS and CTS data; c the unknown vector of random effect parameters; and e is the unknown random error vector. An important component in our estimation was the number of IDUs. Since Brady et al. [27] described the trend of population prevalence of IDUs as a quadratic polynomial, we chose the quadratic polynomial for study year as our best model. The study year was centered on 1997 to diminish correlations between study year polynomials [35] . Instead of using a simple average [14, 27] we used LMM to compute the restricted-maximum-likelihood average as our final estimates for the following three reasons: (1) The TEDS data-series had 5% missing cells and CTS had 8% missing cells. The LMM used all available data to estimate parameters under the assumption that data were missing at random (MAR) conditional on observed data; (2) Since we used health service data (i.e., TEDS data on treatment entry and CTS data on HIV counseling and testing), sudden increases or decreases in health services funding for IDUs might affect our prevalence estimates. LMM helped to smooth the data so the overall trend would not be unduly affected by temporary changes in services that did not reflect true changes in prevalence; and (3) LMM let us compute the uncertainty (standard error) associated with our estimations, which would not have been possible using simple averages.
Reliability
To assess the reliability of the final estimates, we examined the correlations between TEDS-and CTS-based estimates of young IDUs per 10,000 youth for each year.
Criterion Validity
Since injection drug use is associated with fatal overdose, we used overdose deaths among youth to test criterion validity [14, 36] . We examined two types of overdose deaths; (a) drug-related deaths among young people aged 15-29; and (b) accidental and unintentional drug poisoning deaths among 15-29 year olds.
Our algorithm for ''drug-related deaths'' variable was adapted from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). They use ICD-9 and ICD-10 codes to capture ''deaths happening shortly after consumption of one or more psychoactive drugs and directly related to this consumption'' [37] . For ''accidental and unintentional drug poisoning deaths,'' we included only those overdose deaths that occurred due to consumption of cocaine, heroin, or psycho-stimulants.
The number of people dying from either of these causes in each MSA and year was extracted from the National Center for Health Statistics' Multiple Cause of Death database, a census of all deaths in the U.S. [38] . This data series used the ICD-9 coding system to identify causes of death between 1992 and 1998; ICD-10 coding was used thereafter [38] . We restricted our analysis to overdose cases where residency (MSA) and death occurrence (MSA) matched. Neither the ICD-9 nor the ICD-10 coding systems identify the mode of drug administration, so we could not limit overdose cases to those that were IDU related.
Hypothesis Development and Exploration
In preliminary analyses, we observed an apparent decline of young IDU prevalence between 1992 and 1996 and an increase thereafter. This led us to hypothesize that the prevalence of young drug injectors increased after HAART was discovered in 1996. To explore the hypothesis, a number of different analyses were performed:
1. A trend analysis on the percentages of 15-29 year olds who entered drug abuse treatment (TEDS) and reported that they were IDUs. 2. A trend analysis on the percentages of 15-29 year olds who received services at HIV counseling and testing sites (CTS) and reported that they were IDUs.
Two sets of models were calculated for each of these to see if 1996 was the starting point of a rise in IDU prevalence among young people: (1) Results Figure 1 shows the overall trajectory of young IDU population prevalence based on the LMM and considering both fixed effects and random effects. This figure also includes trajectories of young IDU population prevalence based separately on estimates from TEDS and from CTS data. Annual estimates for each MSA appear in the Appendixsupplementary material. Table 1 shows the fixed effect and random effect parameters estimates where the study year was centered on 1997. Considering both the instantaneous rate of change parameter (1.72; P = 0.01) and curvature parameter (0.40; P \ 0.001) the average population prevalence of young IDUs trajectory showed an increasing trend after 1995 (see Table 2 ). The fixed-effect coefficient for the source indicator (Table 1) (Fig. 2) of estimates for the five largest MSAs illustrates such variation. Table 2 Reliability Table 3 shows Pearson correlations between TEDS-and CTS-based estimates of the population prevalence of young IDUs for each year. These correlations describe the extent to which our estimates for each data series produce consistent results. Correlations ranged from 0.74 to 0.89, which suggests that our estimates have acceptable to high reliability [39] .
Criterion Validity Table 4 shows that the population prevalence of young IDUs was significantly correlated each year with: (a) drug related deaths per capita; and (b) accidental and unintentional poisoning deaths per capita. These correlations were positive and in the expected direction, reflecting associations with medium to large effect sizes [40] . These results suggest our final estimates had acceptable validity.
Exploring the Hypothesis that IDU Prevalence Among Youth Increased After HAART was Discovered
To test this exploratory hypothesis we first examined the percentages of young IDUs in TEDS and CTS from 1992 to 2005 (Fig. 3) . Trend analyses on percentages of young IDUs in TEDS and CTS for the years 1996-2005 showed significant increases (TEDS linear slope = 1.62, P \ 0.0001; CTS linear slope = 0.54, P \ 0.0001).
Trend analyses on the final estimates of young IDU population prevalence in each MSA for 1996-2002 were also performed. In TEDS, 42 MSAs increased significantly and 6 MSAs decreased significantly (at P \ 0.05). In CTS, 27 MSAs increased significantly and 10 MSAs decreased significantly (at P \ 0.05). These results suggest young IDU prevalence rates increased after 1996, with some local variation.
Discussion
These data suggest that the prevalence of IDUs among adolescents and young adults increased between 1995 and 2002. Further analyses of the proportions of IDUs entering treatment or receiving HIV counseling and testing who were young suggest that this trend may have continued through 2005. This contrasts sharply with our previous finding that the prevalence of IDUs of all ages decreased from the early 1990s to the early 2000s [27] . If the prevalence of IDUs among young people continues to increase, we would expect the overall prevalence of IDUs eventually to increase as well.
One possible explanation for the increase in young IDUs involves community learning, which has influenced drug use patterns in other circumstances [41, 42] . HAART led to dramatic declines in AIDS incidence and mortality, and this seems to have affected public perceptions of the epidemic. Survey data find that the proportion of Americans who considered HIV/AIDS to be the ''most urgent health problem facing this nation today decreased from 38% in 1997 to 17% in 2002'' [43] . In neighborhoods where injection drug use was prevalent, this meant that children and youth no longer observed widespread HIV-related morbidity or mortality among older peers, relatives or neighbors. According to community learning theory, this would have reduced the deterrent effect of the fear of HIV/ AIDS, which in term might mean that young drug users would be more likely to try (and continue in) injecting their drugs. Parallel arguments have been made to explain decreases in condom use among men who have sex with men after HAART was discovered [44] . Future research should consider and test competing explanations for this trend. One such possible explanation might be the increasing use of prescription analgesics by youth to the extent that this leads them to take up injection [45] .
Study Limitations
Data Limitations
Despite the fact that using different data sources helps to balance biases, as each data series has strengths and weaknesses [28] , we could use only two data series due to lack of other usable data. Availability of additional sources might have strengthened our estimates. Since admissions, rather than individuals, are the units of analysis for TEDS data, an individual who entered drug treatment twice or more in a particular year was counted as two or more independent cases [25] . Similar double-counting is also a limitation for HIV counseling and testing data.
Further, since the TEDS and CTS systems only collect data from subsets of United States locations where drug treatment or CDC-HIV counseling and testing take place our estimates may be biased to the extent that the age distributions of IDUs using these sites differ from those at sites that were not included. For example, the HIV CTS data as a whole are considered to only represent somewhere in the range of about 10-17% of all HIV tests in the US. These limitations have been discussed in detail elsewhere [14, 27] . Our analyses of data on deaths from overdose had some limitations. Unfortunately, the data do not indicate whether the decedent injected drugs prior to death, or if other methods of administration were used. Since non-injection modes of drug administration are more common, we should not expect large associations between IDU prevalence estimates and overdose mortality data. In addition, changes in ICD coding from version 9 to version 10 may have resulted in increased measurement error during the later study years. In addition, our estimates of young IDUs include injectors of heroin, cocaine or other psycho-stimulants, and we have no way to construct accurate estimates of young IDUs by primary drug of choice. Since mortality rates due to overdose vary by the drug being used, this probably means that variations by MSA and by year in the relative distribution of drugs being used by young adults will tend to decrease the size of the correlations presented in Table 4 -which may imply that our estimates of criterion validity are underestimates. Finally, overdose deaths in the young age range (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) were sparse in some MSAs, potentially reducing the reliability of overdose deaths as an indicator for IDU prevalence among young people.
Analytical Limitations
The rate of increase in the percentage of young IDUs entering treatment centers was considerably higher than the rate of increase in young IDUs attending HIV counseling and testing centers (Fig. 3) . This finding could be due to causes other than an increase in young IDU prevalence in the population-for example, if younger IDUs increased in their propensity to enter treatment relative to older IDUs. (This could have occurred if treatment centers increasingly solicited young IDUs or if courts increasingly ordered young IDUs to enter treatment.) Thus our study results could be influenced by selection bias.
Conclusion
This study indicates that injection drug use among young people rose in recent years. Given the importance of sexual and injection behaviors as risk factors for HIV among young IDUs, this underscores previous suggestions that programs should implement interventions for younger IDUs [7, [46] [47] [48] . Failure to set up proper intervention programs could lead to widespread increases in HIV transmission that could parallel recent increases in HIV incidence among young MSM [49, 50] . Young IDUs often face other difficulties as well, such as dropping out of or being expelled from school, difficulty gaining training and experience that might help them get good jobs, and resulting difficulties in obtaining health care [1, 51, 52] .
Drug abuse treatment is unlikely to have much impact on current young IDUs given the very low treatment coverage among IDUs overall from 1993 to 2002 in 90 large US MSAs [53] . Further, some studies have found that young IDUs have less access to drug treatment and to and counseling and testing services than older users [46] [47] [48] .
We conclude with some suggestions for action: (1) Prevention programs including harm reduction programs, treatment programs, counseling centers should include young IDUs as a core focus of their intervention structure; (2) funding for such programs should be increased; and (3) future research should study what differentiates MSAs in which injection drug use among youth is decreasing from MSAs in which it is increasing.
